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Background/introduction
Osteoid osteoma (OO), a small painful benign bone
tumor, is the most common bone tumor in children. Pain
is managed with nonsteroidal anti-inflammatory drugs but
minimally invasive techniques, such as CT-guided laser
ablation, have become a standard intervention. However,
the potential for non-target injury is a concern as tissue
temperature cannot be measured with CT and the laser
induces temperatures >90°C for 10 minutes. It also
includes risks from exposure to ionizing radiation, frac-
ture, infection and transmitted thermal damage from the
access needle. Magnetic resonance guided high intensity
focused ultrasound (MRgHIFU) has been used successfully
in small cohorts of adults with OO. The noninvasive nat-
ure of the energy means that procedures do not need to
be conducted in a sterile environment since there is no
mechanical penetration of the bone, reducing the chance
of pathologic fracture and infection.
Methods
A Philips Sonalleve MRgHIFU device is being used to
thermally ablate OO in pediatric patients. MR provides
excellent soft tissue contrast, which enhances the inter-
face between bone and surrounding soft tissues as well as
the highly vascularized core of the OO, known as the
nidus. The nidus is the primary target of thermal OO
treatments since destroying it will prevent regrowth of
this painful lesion. Ten patients will be recruited and
complete age-appropriate and validated surveys (Pediatric
Ouch, and PedsQLTM) to determine how lesion/bone
pain and medication usage affects health-related quality
of life (HRQL) metrics, such as physical, emotional,
social, and school functioning. A planning MRI will be
used to ensure lesion accessibility/patient eligibility and
MR thermometry will measure temperature in the target
and surrounding tissue to ensure patient safety. As
thermal bone ablation is painful, patients will be under
general anesthesia for the treatment. Follow-up on days
2, 7, 14, 30, 90 and 180 following treatment will record
pain, HRQL, and drug usage. Clinical visits on days 30,
90 and 180 will comprise a physical examination and a
diagnostic MRI of the OO. Contrast enhanced MRI will
indicate non-perfused tissues corresponding to the
ablated tissue volume, which should be fully resolved by
day 180.
Results and conclusions
One patient with a 1cm OO on the left femoral head is
currently enrolled in the study and was treated with
MRgHIFU using seven 4mm treatment cells (Fig 1).
Individual treatments were 12s in duration with a power
of 40-60W. Temperatures >55°C were measured at the
bone surface and a thermal dose of 240EM@43°C was
achieved (Fig 2). A small region of non-perfused tissue
was observed in contrast enhanced MRI corresponding
to the thermal dose margins (Fig 3). One week after
treatment the patient is pain free, off medication, and is
consistently sleeping throughout the night. Study assess-
ment of pain, HRQL and medication will follow. It is
expected that MRgHIFU will be effective for reducing
pain and medication usage, leading to an improvement
in HRQL.
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Figure 1 Planned treatment cells to cover the volume of the osteoid osteoma. A total of seven 4mm treatment cells, arranged in a circular
cluster, covered the extent of the 1cm lesion.
Figure 2 Representative thermal map from one of the treatment sonications. A 50W exposure produced a maximum temperature above 55°C at
the bone surface. A small region (approximately 1 x 4 mm) adjacent to the osteoid osteoma reached sufficient temperatures to achieve a
thermal dose of 240EM@43°C, causing necrosis.
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Figure 3 Gadolinium enhanced T1-w image of the osteoid osteoma and treatment area following thermal ablation. A small region of non-
perfused tissue is visible at the bone surface, adjacent to the osteoid osteoma lesion that is approximately the same extent as the thermal dose
contour.
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